Spots Global Cancer Trial Database for Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia

Official Title: Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia

Study ID: NCT01556386

Conditions

Acute Lymphoblastic Leukemia

Interventions

Study Description

Brief Summary: This study is to find out distribution of genetic polymorphisms and genes related to the chemotherapeutic drugs of ALL.

Detailed Description: Cure rate of pediatric ALL dramatically improved over 80%. Resistance to drug and hematologic relapse are remaining problem in ALL treatment. One of the explanations of drug resistance and toxicities is the pharmacogenetic effect. Germline polymorphisms in genes that code for proteins involved in the pharmacokinetics and pharmacodynamics of antileukemic agents are various, and inter-patient variability is the main factor for pharmacogenetic difference. Since multiple chemotherapeutic agents are involved in treating ALL, many genes related to the metabolic pathways of those drugs have an effect on the pharmacokinetics of patients with ALL. In Korea, pharmacogenetic study including multiple genetic loci for pediatric ALL has not been reported.In this study, the distribution of genetic polymorphisms and genes related to antileukemic drugs were analyzed, and their relations to the outcome of treatment and relapse rates were assessed.